Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com



Growth: Good revenue growth rate 36.8%, there is acceleration compared to average historical growth rates 12.1%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -19.1%

Profitability: LTM EBITDA margin is positive, +23.1%. On average the margin is decreasing unsteadily. Gross margin is high, +80.4%. In the last quarter the company did not beat the estimated EPS, -6.4%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.6%. Free cash flow yield -0.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 301.0% higher than minimum and 8.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.6x by EV / Sales multiple , the company can be 82.8% overvalued

Insiders: For the last 3 months insiders sold company shares on $465.5 mln (-0.071% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-1.1%)723.955
year average price 583.18  


year start price 390.35 2023-04-27

min close price 390.35 2023-04-27

max close price 792.28 2024-03-04

current price 723.96 2024-04-25
Common stocks: 903 782 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.4%
EV / LTM EBITDA: 90.6x
EV / EBITDA annualized: 197.3x
Last revenue growth (y/y):  36.8%
Last growth of EBITDA (y/y):  -57.8%
Historical revenue growth:  12.1%
Historical growth of EBITDA:  7.8%
EV / Sales: 21.0x
Margin (EBITDA LTM / Revenue): 23.1%
Fundamental value created in LTM:
Market Cap ($m): 654 297
Net Debt ($m): 17 761
EV (Enterprise Value): 672 058
Price to Book: 61.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-25Zacks Investment Research

Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics

2024-04-24Zacks Investment Research

Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

2024-04-24Zacks Investment Research

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

2024-04-23Zacks Investment Research

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

2024-04-22Zacks Investment Research

Eli Lilly (LLY) Advances But Underperforms Market: Key Facts

2024-04-22Reuters

Eli Lilly to acquire manufacturing facility from Nexus Pharma

2024-04-20The Motley Fool

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

2024-04-20CNBC

Most people on weight loss drugs are spending less on restaurants and takeout, survey says

2024-04-20The Motley Fool

3 Relatively Safe Growth Stocks You Can Buy and Hold

2024-04-18Proactive Investors

Big pharma: cautious optimism ahead of earnings season - analysts
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LLY LLY LLY LLY LLY LLY
reportedCurrency USD USD USD USD USD USD
cik 59 478 59 478 59 478 59 478 59 478 59 478
fillingDate 2024-02-21 2023-11-02 2023-08-08 2023-04-27 2023-02-22 2022-11-01
acceptedDate 2024-02-21 11:44:37 2023-11-02 11:21:53 2023-08-08 13:23:19 2023-04-27 11:56:56 2023-02-22 10:26:53 2022-11-01 11:16:21
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 9 353M 9 499M 8 312M 6 960M 7 302M 6 942M
costOfRevenue 1 659M 1 860M 1 807M 1 627M 1 548M 1 579M
grossProfit 7 694M 7 639M 6 505M 5 333M 5 754M 5 363M
grossProfitRatio 0.823 0.804 0.783 0.766 0.788 0.773
researchAndDevelopmentExpenses 2 563M 2 409M 2 357M 1 985M 1 996M 1 803M
generalAndAdministrativeExpenses 1 463M 1 804M 1 925M 1 749M 0 0
sellingAndMarketingExpenses 462M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1 925M 1 804M 1 925M 1 749M 1 643M 1 614M
otherExpenses -129M 53M 38M 104M 319M 0
operatingExpenses 4 616M 4 213M 4 282M 3 734M 3 639M 3 417M
costAndExpenses 6 275M 6 073M 6 089M 5 361M 5 187M 4 996M
interestIncome 45M 49M 46M 34M 26M 20M
interestExpense 94M 125M 120M 103M 84M 82M
depreciationAndAmortization 388M 5 950M 366M 210M 556M 363M
ebitda 3 604M 6 401M 2 320M 1 704M 2 393M 2 010M
ebitdaratio 0.385 0.674 0.279 0.245 0.328 0.290
operatingIncome 3 078M 450M 2 126M 1 494M 1 836M 1 647M
operatingIncomeRatio 0.329 0.047 0.256 0.215 0.251 0.237
totalOtherIncomeExpensesNet -569M -2 923M -60M 36M 260M -82M
incomeBeforeTax 2 509M 427M 2 089M 1 530M 2 096M 1 566M
incomeBeforeTaxRatio 0.268 0.045 0.251 0.220 0.287 0.226
incomeTaxExpense 319M 485M 326M 185M 159M 114M
netIncome 2 190M -57M 1 763M 1 345M 1 938M 1 452M
netIncomeRatio 0.234 -0.006 0.212 0.193 0.265 0.209
eps 2.310 -0.064 1.960 1.490 2.040 1.610
epsdiluted 2.310 -0.064 1.950 1.490 2.040 1.610
weightedAverageShsOut 949M 900M 900M 903M 950M 901M
weightedAverageShsOutDil 949M 900M 903M 903M 950M 904M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LLY LLY LLY LLY LLY LLY
reportedCurrency USD USD USD USD USD USD
cik 59 478 59 478 59 478 59 478 59 478 59 478
fillingDate 2024-02-21 2023-11-02 2023-08-08 2023-04-27 2023-02-22 2022-11-01
acceptedDate 2024-02-21 11:44:37 2023-11-02 11:21:53 2023-08-08 13:23:19 2023-04-27 11:56:56 2023-02-22 10:26:53 2022-11-01 11:16:21
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 2 819M 2 381M 2 695M 3 546M 2 067M 2 617M
shortTermInvestments 109M 113M 135M 123M 145M 125M
cashAndShortTermInvestments 2 928M 2 494M 2 829M 3 669M 2 212M 2 742M
netReceivables 11 336M 10 364M 9 171M 9 022M 8 559M 8 325M
inventory 5 773M 4 901M 4 799M 4 545M 4 310M 3 831M
otherCurrentAssets 150M 5 248M 4 532M 3 575M 2 954M 2 742M
totalCurrentAssets 25 727M 23 007M 21 332M 20 811M 18 035M 17 640M
propertyPlantEquipmentNet 12 914M 11 863M 11 277M 10 546M 10 144M 9 311M
goodwill 4 940M 4 085M 4 079M 4 073M 4 073M 3 892M
intangibleAssets 6 907M 6 782M 6 904M 7 087M 7 207M 7 124M
goodwillAndIntangibleAssets 11 846M 10 867M 10 982M 11 160M 11 280M 11 016M
longTermInvestments 3 052M 2 692M 2 745M 2 750M 2 902M 2 575M
taxAssets 5 477M 4 575M 3 806M 3 407M 2 793M 2 384M
otherNonCurrentAssets 4 990M 4 912M 4 672M 4 488M 4 337M 4 536M
totalNonCurrentAssets 38 279M 34 909M 33 482M 32 352M 31 455M 29 822M
otherAssets 0 0 0 0 0 0
totalAssets 64 006M 57 916M 54 814M 53 163M 49 490M 47 462M
accountPayables 2 599M 2 435M 2 474M 2 016M 1 931M 1 683M
shortTermDebt 6 905M 2 245M 662M 3M 1 501M 1 745M
taxPayables 0 1 978M 1 234M 1 528M 475M 686M
deferredRevenue 14 509M 1 978M 1 234M 0 0 0
otherCurrentLiabilities 3 281M 15 341M 14 545M 13 991M 13 707M 12 225M
totalCurrentLiabilities 27 293M 21 998M 18 915M 16 010M 17 138M 15 653M
longTermDebt 18 321M 17 924M 18 158M 18 881M 14 738M 14 144M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 87M 172M
otherNonCurrentLiabilities 7 529M 6 686M 6 591M 6 978M 6 751M 18 215M
totalNonCurrentLiabilities 25 849M 24 610M 24 750M 25 858M 21 576M 21 643M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 1 107M 0 0 0 0 0
totalLiabilities 53 143M 46 608M 43 665M 41 868M 38 714M 37 296M
preferredStock 0 0 0 0 0 0
commonStock 594M 594M 594M 594M 594M 594M
retainedEarnings 10 312M 10 310M 10 369M 10 639M 10 043M 10 007M
accumulatedOtherComprehensiveIncomeLoss -4 327M -3 785M -3 789M -3 777M -3 845M -4 296M
othertotalStockholdersEquity 4 193M 4 102M 3 890M 3 735M 3 858M 3 765M
totalStockholdersEquity 10 772M 11 220M 11 064M 11 190M 10 650M 10 070M
totalEquity 10 864M 11 307M 11 149M 11 190M 10 650M 10 070M
totalLiabilitiesAndStockholdersEquity 64 006M 57 916M 54 814M 53 163M 49 490M 47 366M
minorityInterest 92M 87M 86M 105M 126M 0
totalLiabilitiesAndTotalEquity 64 006M 57 916M 54 814M 53 163M 49 490M 47 366M
totalInvestments 3 161M 2 805M 2 880M 2 874M 3 047M 2 699M
totalDebt 25 225M 20 168M 18 820M 18 884M 16 239M 15 888M
netDebt 22 407M 17 788M 16 126M 15 338M 14 172M 13 271M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LLY LLY LLY LLY LLY LLY
reportedCurrency USD USD USD USD USD USD
cik 59 478 59 478 59 478 59 478 59 478 59 478
fillingDate 2024-02-21 2023-11-02 2023-08-08 2023-04-27 2023-02-22 2022-11-01
acceptedDate 2024-02-21 11:44:37 2023-11-02 11:21:53 2023-08-08 13:23:19 2023-04-27 11:56:56 2023-02-22 10:26:53 2022-11-01 11:16:21
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 2 190M -57M 1 763M 1 345M 1 938M 1 452M
depreciationAndAmortization 388M 411M 366M 362M 375M 363M
deferredIncomeTax -506M -844M -431M -559M 10M -1 071M
stockBasedCompensation 120M 216M 162M 131M 93M 85M
changeInWorkingCapital -3 172M 793M -840M 164M -836M 939M
accountsReceivables -2 451M 0 0 0 0 0
inventory -1 425M 0 0 0 0 0
accountsPayables 4 274M 0 0 0 0 0
otherWorkingCapital -3 571M 793M 0 0 0 0
otherNonCashItems 669M 1 671M -388M 288M -300 000 417M
netCashProvidedByOperatingActivities -312M 2 190M 632M 1 731M 1 580M 2 185M
investmentsInPropertyPlantAndEquipment -1 651M -4 001M -836M -904M -556M -620M
acquisitionsNet -1 625M -1 427M -98M 0 -327M 0
purchasesOfInvestments -275M -151M -234M -169M -169M -255M
salesMaturitiesOfInvestments 69M 133M 155M 343M 129M 109M
otherInvestingActivites 558M 2 365M 555M 40M 62M -160M
netCashUsedForInvestingActivites -2 924M -3 081M -459M -689M -861M -923M
debtRepayment -4 594M -1 595M 0 0 0 0
commonStockIssued 0 0 0 0 0 0
commonStockRepurchased 0 0 0 -750M 0 0
dividendsPaid -1 018M -1 016M -1 018M -1 017M -884M -882M
otherFinancingActivites 9 157M 3 183M -16M 2 180M -257M -381M
netCashUsedProvidedByFinancingActivities 3 545M 572M -1 033M 412M -1 141M -1 263M
effectOfForexChangesOnCash 129M 5M 9M 25M -128M -4M
netChangeInCash 438M -314M -851M 1 479M -550M -6M
cashAtEndOfPeriod 2 819M 2 381M 2 695M 3 546M 2 067M 2 617M
cashAtBeginningOfPeriod 2 381M 2 695M 3 546M 2 067M 2 617M 2 623M
operatingCashFlow -312M 2 190M 632M 1 731M 1 580M 2 185M
capitalExpenditure -1 651M -4 001M -836M -904M -556M -620M
freeCashFlow -1 963M -1 812M -204M 827M 1 024M 1 565M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-06 11:45 ET
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
2024-01-25 13:00 ET
Johna Norton to Retire as Lilly Executive Vice President of Global Quality
2024-01-23 17:00 ET
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
2024-01-23 15:00 ET
Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance
2024-01-04 12:30 ET
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™
2024-01-02 15:00 ET
Lilly to Participate in J.P. Morgan Healthcare Conference
2023-12-27 13:31 ET
Lilly Completes Acquisition of POINT Biopharma
2023-12-18 11:45 ET
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
2023-12-12 00:30 ET
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
2023-12-11 15:54 ET
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
2023-12-08 16:25 ET
Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend
2023-12-05 13:15 ET
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium
2023-12-05 12:38 ET
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity
2023-12-04 11:45 ET
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
2023-12-01 22:22 ET
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
2023-11-28 13:00 ET
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego
2023-11-17 13:00 ET
Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany
2023-11-17 11:45 ET
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
2023-11-14 21:33 ET
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
2023-11-14 15:00 ET
Lilly to Participate in Evercore ISI HealthCONx Conference
2023-11-13 12:30 ET
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
2023-11-08 21:56 ET
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
2023-11-08 17:22 ET
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
2023-11-02 13:00 ET
Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting
2023-11-02 10:30 ET
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
2023-11-01 12:00 ET
Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
2023-11-01 10:55 ET
Lilly Declares Fourth-Quarter 2023 Dividend
2023-10-26 22:24 ET
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
2023-10-26 14:00 ET
Lilly to Participate in UBS Biopharma Conference 2023
2023-10-21 14:31 ET
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress...
2023-10-20 14:00 ET
Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement
2023-10-20 12:00 ET
Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
2023-10-20 10:45 ET
Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years
2023-10-15 22:00 ET
Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks
2023-10-12 10:45 ET
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
2023-10-06 11:45 ET
Lilly Announces Details of Presentations at ESMO Congress 2023
2023-10-04 16:05 ET
Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-10-04 10:45 ET
Lilly Announces Leadership Transitions
2023-10-03 10:45 ET
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
2023-10-02 10:45 ET
U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer
2023-09-22 12:33 ET
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
2023-08-29 14:00 ET
Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-22 11:45 ET
Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
2023-08-14 13:09 ET
Lilly Completes Acquisition of Versanis Bio
2023-08-14 11:25 ET
Lilly Completes Acquisition of Sigilon Therapeutics
2023-08-08 10:45 ET
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
2023-08-04 11:45 ET
Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell L...
2023-07-27 10:48 ET
Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies
2023-07-25 14:00 ET
Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement
2023-07-25 12:14 ET
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
2023-07-25 10:55 ET
Lilly Announces Extension of Tender Offer to Acquire DICE
2023-07-17 14:15 ET
Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA
2023-07-14 12:05 ET
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
2023-07-14 12:00 ET
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
2023-07-11 14:00 ET
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC
2023-07-06 11:45 ET
New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
2023-06-29 10:45 ET
Lilly to Acquire Sigilon Therapeutics
2023-06-26 22:00 ET
Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight
2023-06-26 15:06 ET
Lilly Declares Third-Quarter 2023 Dividend
2023-06-24 15:18 ET
Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes
2023-06-24 01:50 ET
Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight
2023-06-21 17:15 ET
US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older
2023-06-20 17:37 ET
Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions
2023-06-20 12:00 ET
Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap"
2023-06-20 10:45 ET
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
2023-06-16 16:00 ET
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention
2023-06-02 12:00 ET
Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting
2023-05-30 14:00 ET
Lilly to Participate in Goldman Sachs Global Healthcare Conference
2023-05-22 14:00 ET
Lilly ESG Report Highlights Progress Towards Sustainability Goals
2023-05-18 10:45 ET
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
2023-05-11 14:00 ET
Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
2023-05-09 13:23 ET
Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform
2023-05-09 13:00 ET
Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation
2023-05-09 10:45 ET
Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis
2023-05-03 14:00 ET
Lilly to Participate in Bank of America Securities 2023 Healthcare Conference
2023-05-03 10:00 ET
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
2023-05-02 14:00 ET
Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana
2023-05-01 17:02 ET
Lilly Declares Second-Quarter 2023 Dividend
2023-05-01 10:45 ET
Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
2023-04-27 10:45 ET
Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum
2023-04-27 10:15 ET
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
2023-04-17 15:00 ET
Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities
2023-04-13 20:30 ET
U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab
2023-04-13 14:00 ET
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement
2023-03-14 20:30 ET
Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting
2023-03-08 22:00 ET
Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
2023-03-08 14:00 ET
US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes
2023-03-06 15:30 ET
Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study
2023-03-03 19:58 ET
U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
2023-03-01 13:00 ET
Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month
2023-02-27 13:00 ET
Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
2023-02-21 15:00 ET
Lilly to Participate in Cowen's 43rd Annual Health Care Conference
2023-02-13 11:00 ET
Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh
2023-02-07 15:00 ET
Lilly to Participate in SVB Securities Global Biopharma Conference
2023-02-03 15:00 ET
Lilly to Participate in Guggenheim Oncology Conference
2023-02-02 11:45 ET
Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook
2023-01-27 19:07 ET
U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor
2023-01-26 15:00 ET
Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity
2023-01-24 14:00 ET
Be Nimble Foundation to Source Talent within Lilly's Skills First Program
2023-01-24 11:30 ET
Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park
2023-01-20 14:00 ET
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
2023-01-19 23:00 ET
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
2023-01-19 15:00 ET
Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement
2023-01-04 15:00 ET
Lilly to Participate in the J.P. Morgan Healthcare Conference
2022-12-22 11:00 ET
Lilly and ProQR to Expand RNA Editing Collaboration
2022-12-14 09:15 ET
Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
2022-12-13 11:45 ET
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines
2022-12-12 22:30 ET
Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting
2022-12-12 20:26 ET
Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend
2022-12-07 13:00 ET
Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
2022-12-06 20:00 ET
Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology
2022-12-01 13:41 ET
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
2022-11-30 23:00 ET
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
2022-11-30 11:50 ET
Lilly and Akouos Announce Expiration of Akouos Tender Offer
2022-11-29 15:00 ET
Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement
2022-11-21 14:00 ET
Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium
2022-11-16 15:00 ET
Lilly to Participate in Evercore ISI HealthCONx Conference
2022-11-07 16:30 ET
Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform
2022-11-04 14:30 ET
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
2022-11-03 13:00 ET
Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting
2022-11-01 10:25 ET
Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress
2022-10-27 14:00 ET
Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration
2022-10-19 14:00 ET
Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement
2022-10-18 10:50 ET
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
2022-10-17 16:04 ET
Lilly Declares Fourth-Quarter 2022 Dividend
2022-10-06 10:45 ET
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
2022-09-21 23:12 ET
FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
2022-09-08 12:15 ET
Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials
2022-09-07 22:05 ET
Lilly Announces Details of Presentations at ESMO Congress 2022
2022-08-31 14:00 ET
Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-25 14:00 ET
Lilly to Participate in Citi's 17th Annual BioPharma Conference
2022-08-11 12:30 ET
Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly
2022-08-08 10:45 ET
Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience
2022-08-04 13:52 ET
Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results
2022-08-04 10:25 ET
Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements
2022-07-21 14:00 ET
Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement
2022-06-29 10:45 ET
Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
2022-06-27 17:26 ET
Lilly Declares Third-Quarter 2022 Dividend
2022-06-27 00:00 ET
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
2022-06-21 00:00 ET
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma
2022-06-07 04:01 ET
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
2022-06-06 23:00 ET
New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®
2022-06-05 20:30 ET
Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
2022-06-04 15:00 ET
Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo
2022-06-04 14:02 ET
Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
2022-06-03 14:00 ET
Lilly to Participate in Goldman Sachs Global Healthcare Conference
2022-05-26 21:00 ET
Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-26 12:00 ET
Bigfoot Biomedical® Strengthens Leadership Team with Experienced Chief Commercial Officer
2022-05-25 17:15 ET
Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana
2022-05-24 07:01 ET
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
2022-05-23 21:00 ET
Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA
2022-05-16 18:00 ET
Lilly to Participate in UBS Global Healthcare Conference 2022
2022-05-13 21:54 ET
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
2022-05-06 18:00 ET
Mary Lynne Hedley Elected to Lilly Board of Directors
2022-05-03 18:00 ET
Lilly to Participate in Bank of America Securities 2022 Healthcare Conference
2022-05-02 18:26 ET
Lilly Declares Second-Quarter 2022 Dividend
2022-04-28 13:00 ET
IgGenix Announces Move of Headquarters to Lilly Gateway Labs in South San Francisco
2022-04-28 10:25 ET
Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022
2022-04-28 10:15 ET
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
2022-04-20 13:00 ET
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
2022-04-19 14:00 ET
Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement
2022-04-11 14:15 ET
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
2022-04-01 10:45 ET
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
2022-03-28 00:00 ET
Innovent and Lilly Expand Strategic Partnership in Oncology
2022-03-26 13:20 ET
Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies
2022-03-24 10:45 ET
Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
2022-03-16 12:00 ET
Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
2022-03-08 21:30 ET
Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)
2022-03-03 19:00 ET
Lilly to Participate in Barclays Global Healthcare Conference
2022-03-01 15:06 ET
Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial
2022-02-28 19:00 ET
Lilly to Participate in Cowen Health Care Conference
2022-02-24 21:15 ET
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
2022-02-22 11:45 ET
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
2022-02-18 15:45 ET
Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study
2022-02-16 14:00 ET
Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence
2022-02-11 20:08 ET
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
2022-02-10 22:01 ET
Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
2022-02-10 15:00 ET
Cynthia Cardona Elected as President of the Lilly Foundation
2022-02-03 11:25 ET
Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients
2022-02-02 15:00 ET
UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents
2022-02-01 19:00 ET
Lilly to Participate in Guggenheim Oncology Conference
2022-01-28 17:15 ET
Lilly announces $1 billion investment in new manufacturing facility in North Carolina
2022-01-22 00:00 ET
Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022
2022-01-20 15:00 ET
Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement
2022-01-06 19:00 ET
Lilly to Participate in the J.P. Morgan Healthcare Conference
2022-01-06 11:45 ET
Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications
2021-12-21 05:01 ET
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
2021-12-15 11:45 ET
Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting
2021-12-14 22:00 ET
Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
2021-12-13 20:35 ET
Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend
2021-12-13 11:00 ET
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
2021-12-13 11:00 ET
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
2021-12-12 14:30 ET
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting
2021-12-10 11:30 ET
Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
2021-12-09 15:29 ET
New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients
2021-12-03 19:51 ET
Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12
2021-12-03 04:30 ET
Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications
2021-12-01 15:00 ET
Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting
2021-11-18 13:00 ET
Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients
2021-11-17 15:00 ET
Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference
2021-11-11 18:30 ET
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
2021-11-11 13:30 ET
Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care
2021-11-09 19:00 ET
Lilly to Participate in Wolfe Research Virtual Healthcare Conference
2021-11-05 19:00 ET
Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status
2021-11-04 13:00 ET
Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting
2021-11-02 10:45 ET
Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19
2021-11-01 16:00 ET
Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference
2021-10-28 20:00 ET
Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology
2021-10-26 10:25 ET
Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential
2021-10-19 10:45 ET
Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk
2021-10-18 18:52 ET
Lilly Declares Fourth-Quarter 2021 Dividend
2021-10-14 17:30 ET
Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology
2021-10-13 10:45 ET
FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
2021-10-12 14:00 ET
Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement
2021-10-07 13:00 ET
Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
2021-10-04 13:00 ET
Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals
2021-10-01 13:00 ET
At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study
2021-09-30 08:40 ET
Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study
2021-09-30 08:30 ET
Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study
2021-09-29 14:00 ET
Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women
2021-09-28 21:45 ET
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
2021-09-28 10:30 ET
Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options
2021-09-27 12:00 ET
New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary
2021-09-25 00:04 ET
Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency
2021-09-21 20:15 ET
Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities
2021-09-21 17:37 ET
Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19
2021-09-21 11:00 ET
Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due...
2021-09-16 19:56 ET
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
2021-09-15 10:45 ET
Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19
2021-09-13 14:00 ET
Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference
2021-09-13 12:00 ET
Lilly to Present New Data from Oncology Portfolio at ESMO Congress
2021-09-09 18:00 ET
Lilly Prices First Sustainability Bond to Advance Global ESG Strategy
2021-09-09 12:00 ET
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction
2021-09-07 13:00 ET
Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to "Type 1 Diabetes Camps Initiative"
2021-09-07 10:00 ET
Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities
2021-09-03 14:00 ET
Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-31 18:00 ET
Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference
2021-08-29 12:03 ET
Distribution of Etesevimab/JS016 in the US Reopened
2021-08-27 15:25 ET
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
2021-08-25 10:45 ET
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders
2021-08-25 10:45 ET
Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors
2021-08-18 17:30 ET
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
2021-08-17 10:30 ET
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
2021-08-16 11:00 ET
FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps
2021-08-16 06:00 ET
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
2021-08-03 10:25 ET
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
2021-07-29 19:00 ET
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
2021-07-29 10:45 ET
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
2021-07-22 14:00 ET
Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement
2021-07-15 14:00 ET
Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab
2021-07-14 10:45 ET
Lilly Announces Acquisition of Protomer Technologies
2021-07-09 10:31 ET
Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study
2021-07-06 10:25 ET
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
2021-06-29 20:27 ET
Lilly Declares Third-Quarter 2021 Dividend
2021-06-26 20:15 ET
Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
2021-06-25 15:30 ET
Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
2021-06-24 12:00 ET
Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin
2021-06-24 10:45 ET
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
2021-06-17 12:00 ET
Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine
2021-06-15 10:45 ET
Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine
2021-06-14 14:00 ET
Lilly to Participate in Guggenheim Biopharma Strategy Series
2021-06-04 13:00 ET
Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting
2021-06-03 14:00 ET
Lilly to Participate in Goldman Sachs Healthcare Conference
2021-06-03 10:45 ET
Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021
2021-06-03 08:55 ET
Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer
2021-06-01 23:01 ET
Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study
2021-05-22 16:16 ET
Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial
2021-05-20 10:45 ET
Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial
2021-05-19 21:00 ET
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
2021-05-18 04:09 ET
U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
2021-05-13 14:00 ET
Lilly to Participate in UBS Global Healthcare Virtual Conference
2021-05-11 10:45 ET
Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
2021-05-06 10:45 ET
Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes
2021-05-05 14:00 ET
Lilly to Participate in Bank of America Securities 2021 Health Care Conference
2021-05-04 14:07 ET
Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries
2021-05-04 11:00 ET
Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe
2021-05-04 10:42 ET
Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements
2021-05-03 19:28 ET
Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization
2021-05-03 14:00 ET
Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity
2021-04-27 10:25 ET
Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance
2021-04-23 14:01 ET
Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis
2021-04-16 10:30 ET
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
2021-04-14 11:00 ET
SciNeuro Pharmaceuticals Announces Exclusive Licensing Agreement with Eli Lilly & Company
2021-04-13 10:30 ET
Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer
2021-04-13 00:00 ET
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
2021-04-12 10:45 ET
Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together
2021-04-11 18:00 ET
Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
2021-04-06 18:30 ET
Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement
2021-04-01 12:00 ET
Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts
2021-03-31 12:30 ET
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
2021-03-25 19:50 ET
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
2021-03-17 10:45 ET
Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021
2021-03-16 10:45 ET
Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
2021-03-13 11:30 ET
Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
2021-03-10 21:30 ET
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)
2021-03-10 12:00 ET
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
2021-03-09 14:00 ET
Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research
2021-03-09 11:45 ET
Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations
2021-03-08 21:30 ET
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
2021-03-08 13:53 ET
Lilly to Participate in Barclays Global Healthcare Conference
2021-03-05 16:31 ET
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
2021-03-05 11:45 ET
Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet
2021-03-04 11:45 ET
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
2021-02-26 17:35 ET
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
2021-02-26 12:00 ET
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
2021-02-25 11:45 ET
Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions
2021-02-24 20:00 ET
Lilly to Participate in Cowen Health Care Conference
2021-02-17 11:45 ET
Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
2021-02-17 11:30 ET
Kimberly H. Johnson Elected to Lilly Board of Directors
2021-02-11 21:30 ET
Lilly To Participate in SVB Leerink Global Healthcare Conference
2021-02-10 07:45 ET
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
2021-02-10 00:29 ET
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19
2021-02-09 12:00 ET
Lilly Appoints Anat Ashkenazi Chief Financial Officer
2021-02-04 21:30 ET
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference
2021-02-03 22:16 ET
Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
2021-02-03 04:30 ET
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
2021-02-01 12:30 ET
Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients
2021-01-29 11:20 ET
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results
2021-01-28 13:00 ET
Lilly, Life for a Child and Beyond Type 1 advance partnership to improve diabetes care in resource-limited countries
2021-01-28 11:34 ET
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
2021-01-26 15:35 ET
New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
2021-01-26 11:45 ET
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent
2021-01-22 13:55 ET
Lilly Completes Acquisition of Prevail Therapeutics
2021-01-21 13:00 ET
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
2021-01-15 22:02 ET
Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement
2021-01-15 11:45 ET
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund
2021-01-14 11:45 ET
Gabrielle Sulzberger Elected to Lilly Board of Directors
2021-01-11 13:00 ET
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
2021-01-11 11:30 ET
Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
2021-01-04 20:30 ET
Lilly to Participate in J.P. Morgan Healthcare Conference
2020-12-21 14:00 ET
Principle LTC's Tower Nursing & Rehabilitation Center Joins with Eli Lilly and Company on Phase 3 Drug Trial for COVID-19 Prevention
2020-12-18 22:00 ET
Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
2020-12-15 11:30 ET
Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance
2020-12-15 11:15 ET
Lilly Announces Agreement to Acquire Prevail Therapeutics
2020-12-14 21:05 ET
Lilly Announces 15 Percent Dividend Increase
2020-12-14 16:05 ET
Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study
2020-12-09 14:00 ET
Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®
2020-12-09 11:45 ET
Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
2020-12-08 11:45 ET
Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement
2020-12-07 15:00 ET
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting
2020-12-05 17:30 ET
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting
2020-12-04 13:00 ET
Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19
2020-12-02 21:30 ET
Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19
2020-11-24 20:00 ET
Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference
2020-11-20 21:23 ET
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19
2020-11-19 11:45 ET
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
2020-11-18 13:00 ET
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
2020-11-12 17:35 ET
Lilly to Participate in Wolfe Research Virtual Healthcare Conference
2020-11-12 17:30 ET
Lilly to Participate in Bernstein Operational Decisions Conference
2020-11-11 21:15 ET
Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program
2020-11-09 23:32 ET
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19
2020-11-05 14:00 ET
Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting
2020-11-05 11:30 ET
Aarti Shah to Retire as Lilly Chief Information and Digital Officer
2020-11-05 00:00 ET
Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT® (sintilimab injection) to Be Presented at the ESMO ASIA Congress 2020
2020-10-29 11:00 ET
New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis
2020-10-28 21:16 ET
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine
2020-10-28 10:45 ET
Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19
2020-10-27 10:30 ET
Lilly Reports Third-Quarter Financial Results, Updates Guidance
2020-10-23 14:45 ET
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
2020-10-19 16:15 ET
Lilly Declares Fourth-Quarter 2020 Dividend
2020-10-15 13:20 ET
Lilly Announces Agreement to Acquire Disarm Therapeutics
2020-10-12 10:45 ET
Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial
2020-10-09 11:10 ET
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China
2020-10-09 10:45 ET
Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment
2020-10-08 20:15 ET
Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement
2020-10-08 12:45 ET
Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity
2020-10-08 10:45 ET
Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries
2020-10-07 12:30 ET
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
2020-10-07 10:30 ET
Lilly and Dexcom team up on new program to help improve diabetes management
2020-10-06 10:45 ET
REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study
2020-09-21 00:36 ET
Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020
2020-09-21 00:00 ET
Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020
2020-09-20 18:01 ET
Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer
2020-09-17 10:30 ET
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
2020-09-16 20:56 ET
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
2020-09-16 10:45 ET
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
2020-09-15 15:00 ET
Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care
2020-09-15 12:00 ET
US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack
2020-09-14 10:00 ET
Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
2020-09-11 19:00 ET
Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference
2020-09-11 16:00 ET
Lilly to Participate in Morgan Stanley Global Healthcare Conference
2020-09-11 10:45 ET
REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study
2020-09-10 20:30 ET
Lilly Announces Webcast to Discuss ESMO 2020 Presentations
2020-09-10 16:00 ET
Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes
2020-09-10 10:45 ET
Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020
2020-09-09 10:30 ET
Lilly Announces Leadership Changes
2020-09-03 21:12 ET
FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes
2020-08-29 10:00 ET
Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction
2020-08-27 10:45 ET
New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers
2020-08-18 10:30 ET
Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement
2020-08-18 10:30 ET
Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement
2020-08-12 08:40 ET
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
2020-08-08 13:00 ET
Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020 Virtual Presidential Symposium
2020-08-03 10:45 ET
Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
2020-07-30 10:25 ET
Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance
2020-07-30 10:15 ET
Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
2020-07-28 17:13 ET
Lilly's P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA
2020-07-21 13:00 ET
Data from Lilly at Alzheimer's Association International Conference 2020® (AAIC® 2020) to Showcase Clinical Advances in Alzheimer's Research
2020-07-17 18:00 ET
Lilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement
2020-07-17 10:45 ET
Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
2020-07-15 19:30 ET
Lilly Declares Third-Quarter 2020 Dividend
2020-06-25 12:00 ET
Central Indiana Racial Equity Fund Launches with more than $2.2 Million in Initial Commitments
2020-06-24 12:30 ET
Lilly launches program about what people with diabetes should "Know Before the Low™"
2020-06-20 00:37 ET
Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
2020-06-19 16:25 ET
Full results from EMPERIAL exercise ability trials presented
2020-06-18 12:00 ET
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
2020-06-17 10:45 ET
Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine
2020-06-16 15:00 ET
Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications
2020-06-16 10:45 ET
Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
2020-06-16 02:21 ET
FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin
2020-06-15 10:45 ET
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
2020-06-13 15:15 ET
Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
2020-06-13 15:00 ET
Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice
2020-06-12 19:46 ET
Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life
2020-06-12 19:00 ET
Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)
2020-06-12 15:03 ET
Lilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event
2020-06-10 19:19 ET
EULAR 2020: Lilly Shares New Data for OLUMIANT® in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)
2020-06-09 10:45 ET
First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial
2020-06-08 15:00 ET
Lilly to Participate in Goldman Sachs Global Healthcare Conference
2020-06-08 11:15 ET
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
2020-06-05 22:09 ET
EULAR 2020: Lilly’s TALTZ® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
2020-06-03 10:45 ET
EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus
2020-06-03 10:45 ET
EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
2020-06-01 10:45 ET
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
2020-06-01 10:30 ET
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
2020-05-30 01:07 ET
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2020-05-28 23:17 ET
Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease
2020-05-26 21:51 ET
Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model
2020-05-26 12:00 ET
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction
2020-05-26 10:45 ET
Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
2020-05-19 13:00 ET
Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease
2020-05-13 21:00 ET
Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020
2020-05-09 00:22 ET
Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers
2020-05-08 18:20 ET
Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes
2020-05-05 20:30 ET
Lilly to Participate in UBS Virtual Global Healthcare Conference
2020-05-04 19:00 ET
Lilly Declares Second-Quarter 2020 Dividend
2020-05-04 12:00 ET
Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19
2020-04-30 20:30 ET
Lilly to Participate in Bank of America Securities Health Care Conference
2020-04-23 10:25 ET
Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance
2020-04-16 10:45 ET
Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available
2020-04-10 21:11 ET
Lilly Begins Clinical Testing of Therapies for COVID-19
2020-04-08 10:30 ET
Lilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement
2020-04-07 16:00 ET
Eli Lilly and Company to Hold 2020 Annual Meeting of Shareholders Virtually
2020-04-07 10:30 ET
New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.
2020-03-31 10:30 ET
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines
2020-03-30 10:45 ET
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
2020-03-24 12:00 ET
Updates from Lilly about insulin supply and affordability
2020-03-23 10:30 ET
Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic
2020-03-22 20:45 ET
Lilly to Provide Drive-Through COVID-19 Testing for Indianapolis Health Care Workers
2020-03-20 20:30 ET
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
2020-03-20 14:30 ET
Kathryn Beiser to join Lilly as Vice President, Global Communications
2020-03-18 18:45 ET
Lilly, Indiana State Department of Health Partner to Accelerate COVID-19 Testing Using Lilly Research Laboratories
2020-03-16 10:45 ET
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
2020-03-12 22:11 ET
AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19
2020-03-12 12:00 ET
US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease
2020-03-11 16:36 ET
Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D
2020-03-09 16:10 ET
Lilly to Participate in Barclays Global Healthcare Conference
2020-03-03 12:00 ET
Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines
2020-03-02 11:45 ET
U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis
2020-02-27 00:27 ET
FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2020-02-22 00:50 ET
Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease
2020-02-21 20:45 ET
Lilly to Participate in Cowen Health Care Conference
2020-02-21 20:10 ET
Lilly To Participate in SVB Leerink Global Healthcare Conference
2020-02-20 13:55 ET
Lilly Completes Acquisition of Dermira
2020-02-11 23:24 ET
Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis
2020-02-10 06:00 ET
Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study
2020-02-07 19:00 ET
Lilly to Participate in Guggenheim Healthcare Talks Idea Forum
2020-01-31 15:43 ET
Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription
2020-01-31 11:15 ET
CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes
2020-01-30 11:25 ET
Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition
2020-01-30 11:15 ET
Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
2020-01-29 11:45 ET
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
2020-01-28 11:45 ET
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
2020-01-27 22:34 ET
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
2020-01-27 11:45 ET
Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine
2020-01-24 11:30 ET
Anat Hakim to join Lilly as General Counsel
2020-01-23 13:00 ET
Ready for Rescue – New Nasally Administered Glucagon for Severe Hypoglycemia Available in Canada
2020-01-21 17:47 ET
Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant
2020-01-16 20:45 ET
Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement
2020-01-15 11:45 ET
Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease
2020-01-14 11:45 ET
Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®
2020-01-13 11:30 ET
Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
2020-01-13 04:42 ET
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
2020-01-13 04:23 ET
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
2020-01-02 21:30 ET
Lilly to Participate in J.P. Morgan Healthcare Conference
2019-12-16 21:25 ET
Lilly Announces 15 Percent Dividend Increase
2019-12-16 11:45 ET
Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System
2019-12-13 13:00 ET
Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure
2019-12-13 11:47 ET
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2019-12-08 21:30 ET
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
2019-12-02 21:33 ET
Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference
2019-12-02 14:00 ET
Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco
2019-12-02 12:22 ET
Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)
2019-11-26 15:15 ET
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from TALTZ® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
2019-11-26 15:15 ET
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of TALTZ® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
2019-11-20 11:30 ET
Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis
2019-11-19 21:15 ET
Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement
2019-11-17 15:50 ET
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
2019-11-13 22:07 ET
Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
2019-11-12 13:30 ET
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized
2019-11-12 12:00 ET
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
2019-11-12 11:45 ET
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
2019-11-07 17:50 ET
Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities
2019-11-07 14:00 ET
Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities
2019-11-06 14:00 ET
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019
2019-11-04 21:15 ET
Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference
2019-11-04 14:00 ET
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®
2019-11-04 14:00 ET
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®
2019-10-24 14:17 ET
Lilly Announces Cash Tender Offer for Up to $2.0 Billion Aggregate Principal Amount of Its Outstanding Debt Securities
2019-10-23 10:00 ET
Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno
2019-10-21 18:45 ET
Lilly Declares Fourth-Quarter 2019 Dividend
2019-04-18 21:05 ET
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
2019-03-29 00:30 ET
Transcenta Holding Announces Licensing Agreement with Lilly
2019-03-26 20:30 ET
Lilly and ImmuNext Announce Licensing and Research Collaboration
2019-03-12 12:00 ET
EBD Group: BIO-Europe Spring(R) 2019 comes to Vienna in two weeks for 13th annual springtime biopharma conference
2019-03-12 10:45 ET
Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2019-01-29 11:30 ET
Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain

SEC forms

Show financial reports only

SEC form 10
2024-02-21 00:00 ET
Eli Lilly reported for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Eli Lilly published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Eli Lilly published news for 2023 q4
SEC form 10
2023-11-02 11:21 ET
Eli Lilly reported for 2023 q3
SEC form 8
2023-11-02 07:02 ET
Eli Lilly published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Eli Lilly published news for 2023 q3
SEC form 10
2023-08-08 13:23 ET
Eli Lilly reported for 2023 q2
SEC form 6
2023-08-08 07:01 ET
Eli Lilly published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Eli Lilly published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Eli Lilly published news for 2023 q2
SEC form 6
2023-06-22 15:14 ET
Eli Lilly published news for 2023 q1
SEC form 10
2023-04-27 00:00 ET
Eli Lilly reported for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Eli Lilly published news for 2023 q1
SEC form 6
2023-03-17 16:05 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-24 17:00 ET
Eli Lilly published news for 2022 q4
SEC form 10
2023-02-22 10:26 ET
Eli Lilly reported for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Eli Lilly reported for 2022 q4
SEC form 6
2023-02-14 17:19 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-14 17:10 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-14 17:07 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-14 16:43 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-14 16:34 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 17:04 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 17:01 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:57 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:54 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:51 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:45 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-03 16:35 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-02-02 07:13 ET
Eli Lilly published news for 2022 q4
SEC form 8
2023-02-02 00:00 ET
Eli Lilly published news for 2022 q4
SEC form 6
2023-01-03 16:40 ET
Eli Lilly published news for 2022 q4
SEC form 6
2022-12-13 07:03 ET
Eli Lilly published news for 2022 q3
SEC form 8
2022-12-13 00:00 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:34 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:20 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:15 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:11 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-11-22 17:08 ET
Eli Lilly published news for 2022 q3
SEC form 10
2022-11-01 11:16 ET
Eli Lilly reported for 2022 q3
SEC form 6
2022-11-01 07:03 ET
Eli Lilly published news for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Eli Lilly published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Eli Lilly reported for 2022 q3
SEC form 6
2022-10-12 16:08 ET
Eli Lilly published news for 2022 q3
SEC form 6
2022-09-06 16:22 ET
Eli Lilly published news for 2022 q2
SEC form 10
2022-08-04 11:31 ET
Eli Lilly reported for 2022 q2
SEC form 6
2022-08-04 07:05 ET
Eli Lilly published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Eli Lilly published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Eli Lilly reported for 2022 q2
SEC form 6
2022-06-27 16:36 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-05-16 16:51 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-05-06 16:23 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-05-04 15:04 ET
Eli Lilly published news for 2022 q1
SEC form 10
2022-04-29 11:57 ET
Eli Lilly reported for 2022 q1
SEC form 10
2022-04-29 00:00 ET
Eli Lilly reported for 2022 q1
SEC form 6
2022-04-28 07:05 ET
Eli Lilly published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-04-14 16:57 ET
Eli Lilly published news for 2022 q1
SEC form 8
2022-04-14 00:00 ET
Eli Lilly published news for 2022 q1
SEC form 6
2022-03-22 16:58 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-22 16:56 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-22 16:54 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-22 16:52 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-22 16:49 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-18 16:14 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-07 17:06 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-03 18:36 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-03-03 18:30 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-28 16:38 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-25 16:36 ET
Eli Lilly published news for 2021 q4
SEC form 10
2022-02-23 11:00 ET
Eli Lilly published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:45 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:42 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:35 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:19 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:16 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:12 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:09 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-11 18:03 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 17:09 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 17:04 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 16:59 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 16:55 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 16:38 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 16:33 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-02-03 07:08 ET
Eli Lilly published news for 2021 q4
SEC form 8
2022-02-03 00:00 ET
Eli Lilly published news for 2021 q4
SEC form 6
2022-01-31 08:27 ET
Eli Lilly published news for 2021 q4
SEC form 6
2021-12-16 16:04 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-12-15 07:05 ET
Eli Lilly published news for 2021 q3
SEC form 8
2021-12-15 00:00 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:23 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:22 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:20 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:19 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:17 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 17:16 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 16:51 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 16:46 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-11-17 16:42 ET
Eli Lilly published news for 2021 q3
SEC form 10
2021-10-27 09:06 ET
Eli Lilly published news for 2021 q3
SEC form 10
2021-10-27 00:00 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-10-26 07:06 ET
Eli Lilly published news for 2021 q3
SEC form 8
2021-10-26 00:00 ET
Eli Lilly published news for 2021 q3
SEC form 6
2021-09-10 16:54 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-09-07 16:56 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-25 06:54 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-17 17:11 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-17 17:08 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-17 17:06 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-17 06:50 ET
Eli Lilly published news for 2021 q2
SEC form 10
2021-08-03 12:04 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-08-03 07:37 ET
Eli Lilly published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Eli Lilly published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Eli Lilly published news for 2021 q2
SEC form 6
2021-06-30 17:03 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-06-24 15:52 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-05-27 06:52 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-05-19 16:41 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-05-05 06:57 ET
Eli Lilly published news for 2021 q1
SEC form 10
2021-04-30 09:23 ET
Eli Lilly published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-04-27 06:48 ET
Eli Lilly published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
Eli Lilly published news for 2021 q1
SEC form 6
2021-03-19 16:38 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-23 15:57 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-18 17:07 ET
Eli Lilly published news for 2020 q4
SEC form 10
2021-02-17 10:59 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-17 07:04 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-10 20:27 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-10 12:13 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-09 07:14 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 20:22 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 19:26 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 18:57 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 18:51 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 18:43 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-03 18:33 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-02 17:20 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-02 17:16 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-02 17:12 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-02-02 17:09 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-01-29 06:32 ET
Eli Lilly published news for 2020 q4
SEC form 6
2021-01-14 07:30 ET
Eli Lilly published news for 2020 q4
SEC form 6
2020-12-16 20:07 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-12-15 07:27 ET
Eli Lilly reported for 2020 q3
SEC form 6
2020-12-02 20:01 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:33 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:30 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:29 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:25 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:24 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:22 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-11-18 21:20 ET
Eli Lilly published news for 2020 q3
SEC form 10
2020-10-28 10:57 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-10-27 07:50 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-10-07 16:42 ET
Eli Lilly published news for 2020 q3
SEC form 6
2020-10-05 12:19 ET
Eli Lilly published news for 2020 q3